E-CEL UVEC

Phase 1Gene therapy

WWeill Medical College of Cornell University

E-CEL UVEC is one of 16 small molecule programs targeting Rotator Cuff Tears. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rotator Cuff TearsActive, not recruiting

Anal FistulaRecruiting

Anal FissureRecruiting

Rotator Cuff TearsPhase 1

Active, not recruiting

Anal FistulaPhase 1

Recruiting

Anal FissurePhase 1

Recruiting

Competition

Competitive Landscape

10 competitors in Anal Fistula

#DrugCompanyPhaseTrials

Humira

Novartis

Approved

2 2

Acanya

Marcaine

Amoxil

GGlobal Antibiotics Research and Development Partnership

Preclinical

—5

Dilantin

VViatris Specialty LLC

AVB-114

1 7

E-CEL UVEC

WWeill Medical College of Cornell University

Phase 1

1 8

Amoxicillin-Clavulanate

IIterum Therapeutics, International Limited

Preclinical

1 9

Fibrin Glue

FFundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Rotator Cuff Tears

NCT04057833

Phase 1Recruiting

Anal Fissure

NCT06456073

Q2 2032

Phase 1Recruiting

Anal Fistula

NCT04190862

Clinical

Trials by Indication[1]

Anal fissure1 trial

E-CEL UVEC Treatment for Anal Fissures

Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT06456073·12 enrolled

Anal fistula1 trial

E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas

Recruiting·WWeill Medical College of Cornell University·Phase 1·NCT04190862·39 enrolled

Rotator Cuff Tears1 trial

A Phase 1 Open-Label, Single-Center Investigator Initiated Trial (IIT) of E-CEL UVEC Cells as an Adjunct Cell Therapy for the Arthroscopic Rotator Cuff Repair in Adults

Active, not recruiting·HHospital for Special Surgery, New York·Phase 1·NCT04057833·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for E-CEL UVEC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — E-CEL UVEC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for E-CEL UVEC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Weill Medical College of Cornell University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 1[1]
Company: WWeill Medical College of Cornell University

E-CEL UVEC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2032

Trials by Indication[1]

Anal fissure1 trial

Anal fistula1 trial

Rotator Cuff Tears1 trial

References

Drug Info

Quick Facts

Related News